Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell...

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• 40% of diffuse large B-cell lymphoma (DLBCL) patients relapse after immuno-chemotherapy.
• Previous studies lacked a consistent genetic signature for DLBCL relapse.
• Understanding relapse mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate gene expression profile (GEP) changes during DLBCL relapse.
• To identify a novel genetic signature associated with DLBCL relapse.
• To evaluate the clinical utility of this signature in predicting treatment response.

Main Methods:

• Analysis of paired diagnostic and relapse tumor specimens from 38 de novo DLBCL patients.
• Transcriptomic profiling to identify relapse-associated gene expression changes.
• Development and validation of a 30-gene discriminator for activated B-cell-like DLBCL (ABC-DLBCL).

Main Results:

• Gene expression profiling revealed distinct relapse mechanisms in ABC-DLBCL and germinal center B-cell-like DLBCL (GCB-DLBCL).
• A 30-gene signature effectively stratified ABC-DLBCL patients into high- and low-risk subgroups at diagnosis.
• This signature identified younger patients (<60 years) with improved progression-free survival (PFS) and overall survival (OS) when treated with ibrutinib-R-CHOP in the PHOENIX trial.

Conclusions:

• The developed 30-gene signature provides a valuable tool for risk stratification in ABC-DLBCL.
• This genetic signature can identify patients likely to benefit from targeted therapies like ibrutinib-R-CHOP.
• The signature warrants further assessment in prospective clinical trials for DLBCL management.